Pediatric Infection and Vaccine

  • 제30권1호
  • /
  • Pages.47-54
  • /
  • 2023
  • /
  • 2384-1079(pISSN)
  • /
  • 2384-1087(eISSN)
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)
권호 표지
DOI QR코드

DOI QR Code

면역저하 소아에서 발생한 다제내성 녹농균 균혈증을 ceftolozane-tazobactam으로 성공적으로 치료한 증례보고

Treatment of Multidrug-resistant Pseudomonas aeruginosa Bacteremia in a Immunocompromised Child With Ceftolozane-tazobactam

  • 유혜선 (성균관대학교 삼성서울병원 소아청소년과) ;
  • 신아름 (성균관대학교 삼성서울병원 소아청소년과) ;
  • 김두리 (성균관대학교 삼성서울병원 소아청소년과) ;
  • 최재영 (성균관대학교 삼성서울병원 중환자의학과) ;
  • 주희영 (성균관대학교 삼성서울병원 소아청소년과) ;
  • 조중범 (성균관대학교 삼성서울병원 중환자의학과) ;
  • 강철인 (성균관대학교 삼성서울병원 내과) ;
  • 김예진 (성균관대학교 삼성서울병원 소아청소년과)
  • Hyesun Yu (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Areum Shin (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Doo Ri Kim (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jaeyoung Choi (Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Hee Young Ju (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Joongbum Cho (Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Cheol-In Kang (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Yae-Jean Kim (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 투고 : 2022.09.29
  • 심사 : 2023.06.12
  • 발행 : 2023.07.03
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

최근 광범위 항생제 사용의 증가로 인한 다제내성 그람 음성균의 출현이 전 세계적으로 문제가 되고 있다. 특히 다제내성 녹농균(multidrug-resistant Pseudomonas aeruginosa) 감염의 치료는 어려우며 중환자의 사망률을 증가시키는 원인이 된다. 세프톨로잔-타조박탐(ceftolozane-tazobactam, ZerbaxaTM)은 5세대 세팔로스포린과 베타락탐 분해효소저해제로 다제내성 녹농균에 의한 복잡성 요로감염과 복잡성 복강내 감염의 치료에 효과가 있는 것으로 입증되었다. 본지에서 저자들은 소아청소년 혈액암 환자에서 발생한 다제내성 녹농균에 의한 균혈증을 세프톨로잔-타조박탐을 사용하여 성공적으로 치료한 국내 첫 번째 사례를 보고하고자 한다.

With the widespread use of broad-spectrum antibiotics in clinical practice, the emergence of multidrug-resistant (MDR) gram-negative bacteria has become a global problem. The MDR Pseudomonas aeruginosa infection is especially difficult to treat and increases mortality in critically ill patients. Ceftolozane-tazobactam (ZerbaxaTM) is a fifth-generation cephalosporin and beta-lactamase inhibitor that has proved to be effective for treating complicated urinary tract infections and complicated intra-abdominal infections caused by MDR P. aeruginosa. Herein, we report the first case of pediatric hematologic cancer in Korea that was successfully treated for MDR P. aeruginosa bacteremia with Ceftolozane-tazobactam.

키워드

참고문헌

  1. World Health Organization. Antimicrobial resistance [Internet]. Geneva: World Health Organization; 2021 [cited 2022 Oct 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. 
  2. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. London: Government of the United Kingdom, 2016. 
  3. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022;399:629-55. https://doi.org/10.1016/S0140-6736(21)02724-0
  4. Horcajada JP, Montero M, Oliver A, Sorli L, Luque S, Gomez-Zorrilla S, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 2019;32:e00031-19. 
  5. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81. https://doi.org/10.1111/j.1469-0691.2011.03570.x
  6. Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C, et al. P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol 2012;91:1299-304. https://doi.org/10.1007/s00277-012-1424-3
  7. Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, et al. Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica 2010;95:1612-5.  https://doi.org/10.3324/haematol.2009.020867
  8. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018;18:318-27.  https://doi.org/10.1016/S1473-3099(17)30753-3
  9. Bassetti M, Peghin M, Vena A, Giacobbe DR. Treatment of infections due to MDR gram-negative bacteria. Front Med (Lausanne) 2019;6:74. 
  10. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. IDSA guidance on the treatment of antimicrobial-resistant gram-negative infections: version 1.1 [Internet]. Arlington: Infectious Diseases Society of America; 2022 [cited 2022 Oct 25]. Available from: https://www.idsociety.org/practice-guideline/amr-guidance/. 
  11. Karakonstantis S, Kritsotakis EI, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems. Infection 2020;48:835-51.  https://doi.org/10.1007/s15010-020-01520-6
  12. Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, et al. Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed. Antimicrob Agents Chemother 2022;66:e0199121. 
  13. Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J Antimicrob Chemother 2017;72:1386-95.  https://doi.org/10.1093/jac/dkx009
  14. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 2014;74:31-51.  https://doi.org/10.1007/s40265-013-0168-2
  15. Hakeam HA, Askar G, Al Sulaiman K, Mansour R, Al Qahtani MM, Abbara D, et al. Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: a multicenter retrospective study. J Infect Public Health 2022;15:1081-8.  https://doi.org/10.1016/j.jiph.2022.08.020
  16. Merck Sharp & Dohme LLC. Product information. Zerbaxa (ceftolozane-tazobactam) [Internet]. Rahway: Merck Sharp & Dohme LLC; 2022 [cited 2022 Sep 22]. Available from: https://www.merck.com/product/usa/pi_circulars/z/zerbaxa/zerbaxa_pi.pdf.